Modulation effects of hexamethylene bisacetamide on growth and differentiation of cultured human malignant glioma cells

Journal of Neurosurgery

Volumn 84, Issue 5, 1996, Pages 831-838

  Li, Xiao Nan ^a,c   Du, Zi Wei ^a,b   Huang, Qiang ^a  

^a Department of Aging diseases The second affiliated hospital   (China)

^b KEIO UNIVERSITY   (Japan)

^c Suchow University Affiliated Second Hospital   (China)

Author keywords

growth induced differentiation; hexamethylene bisacetamide; human glioma cells

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; HEXAMETHYLENEBISACETAMIDE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL DIFFERENTIATION; COLONY FORMATION; CONTROLLED STUDY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPINDLE CELL; STELLATE CELL; TUMOR GROWTH; XENOGRAFT;

EID: 0029936692     PISSN: 00223085     EISSN: None     Source Type: Journal    
DOI: 10.3171/jns.1996.84.5.0831     Document Type: Article

References (55)

1. Andreeff M, Stone R, Michaeli J, et al: Hexamethylene bisacetamide in myelodysplastic syndrome and acute myelogeneous leukemia: a phase II clinical trail with a differentiation-inducing agent. Blood 80:2604-2609, 1992
2. Beere HM, Hickman JA: Differentialion: a suitable strategy for cancer chemotherapy? Anticancer Drug Des 8:299-322. 1993
3. Bloch A: Induced cell differentiation in cancer therapy. Cancer Treat Rep 68:199-205, 1984
4. Chang CH, Horton J, Schoenfeld D, et al: Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. A joint Radiation Therapy Oncology Group and Eastern Cooperative Oncology Group study. Cancer 52: 997-1007, 1983
5. Chen Z. Banks J, Rifkind RA. et al: Inducer-mediated commitment of murine erythroleukemia cells to differentiation: a multistep process. Proc Natl Acad Sci USA 79:471-475, 1982
6. Colburn NH, Vorder Bruegge WVF, Bates JR, et al: Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res 38: 624-634, 1978
7. Du ZW: [ Establishment of human malignant glioma cell line (SHG-44) and observation on its characteristics.] Chung Hua Chung Liu Tsa Chih 6:241-243, 1984 (Chi)
8. Duffy PE: Glial fibrillary acidic protein and induced differentiation of glia in vitro. J Neurol Sci 53:443-460, 1982
9. Duffy PE, Huang YY, Rapport MM: Glial fibrillary acidic protein in giant cell tumors of brain and other gliomas. A possible relationship to malignancy, differentiation, pleomorphism of glia. Acta Neuropathol 52:51-57, 1980
10. Duffy PE, Huang YY, Rapport MM: The relationship of glial fibrillary acidic protein to the shape, motility, and differentiation of human astrocytoma cells. Exp Cell Res 139:145-157, 1982
11. Ebert PS, Salcman M: Differentiation therapy is potentiated by chemotherapy and hyperthermia in human and canine brain tumor cells in vitro. Neurosurgery 34:657-664, 1994
12. Fibach E, Reuben RC, Rifkind RA et al: Effect of hexamethy-lene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res 37:440-444, 1977
13. Freshney RI: Culture of Animal Cells. A Manual of Basic Technique. New York: Alan R Liss. 1983, pp 159-174
14. Freshney RI: Culture of Animal Cells. A Manual of Basic Technique. New York: Alan R Liss, 1983, pp 129-143
15. Goldman JE, Chiu FC: Growth kinetics, cell shape, and the cytoskeleton of primary astrocyte cultures. J Neurochem 42: 175-184, 1984
16. Guilbaud NF, Gas N, Dupont MA, et al: Effect of differentiation-inducing agents on maturation of human MCF-7 breast cancer cells. J Cell Physiol 145:162-172, 1990
17. Helseth E, Unsgaard G, Dalen A, et al: Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors. Cancer Immunol Immunother 26:273-279, 1988
18. Hsu SM, Raine L, Fanger H, et al: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-592, 1981
19. Huang Q, Du ZW, Xu GD, et al: [Establishment of human glioma cell line - nude mouse solid tumor model NHG-1 and its characteristics.] Chung Hua Chung Liu Tsa Chih 9: 269-272, 1987 (Chi)
20. Jacque CM, Kujas M, Poreau A, et al: GFA and S 100 protein levels as an index for malignancy in human gliomas and neurinomas. J Natl Cancer Inst 62:479-483, 1979
21. Kahn P, Shin SI: Cellular rumorigenicity in nude mice. Test of associations among loss of cell-surface fibroneetin, anchorage independence, and tumor-forming ability. J Cell Biol 82:1-16, 1979
22. Khan MA, Freshney RI, McNiclo AM, et al: Induction of phenotypic changes in small cell lung cancer cell lines in vitro by hexamethylene bisacetamide, sodium butyrate, and cyclic AMP. Ann Oncol 4:499-507, 1993
23. 1. Proc Natl Acad Sci USA 90: 6746-6750, 1993
24. Laiho M, DeCaprio JA, Ludlow JW, et al: Growth inhibition by TGF-β linked to suppression of retinoblastoma protein phosphorylation. Cell 62:175-185, 1990
25. Leng L, Yu F, Dong L, et al: Differential modulation of protein kinase C isoforms in erythroleukemia during induced differentiation. Cancer Res 53:5554-5558, 1993
26. Levine AE, Black B, Brattain MG, et al: Effects of N,N-dimethylformamide and extracellular matrix on transforming growth factor-β binding to a human colon carcinoma cell line. J Cell Physiol 138:459-466, 1989
27. Li XN, Huang Q, Du ZW: Methodologic study of direct preparation for chromosome analysis of human solid brain tumors. Cancer Genet Cytogenet 58:160-164, 1992
28. Lotart R, Sacks GP, Lotan D, et al: Differential effects of retinoic acid on the in vitro growth and cell surface glycoconjugates of 2 human head and neck squamous-cell carcinomas. Int J Cancer 40:224-229, 1987
29. Maria BL, Steck PA, Yung WKA, et al: The modulation of astrocytic differentiation in cells derived from a medulloblastoma surgical specimen. J Neurooncol 7:329-338, 1989
30. Marks PA, Rifkind RA: Differentiation modifiers. Cancer 54 (Suppl II):2766-2769, 1984
31. Marks PA, Sheffery M, Rifkind RA: Induction of transformed cells to terminal differentiation and the modulation of gene expression. Cancer Res 47:659-666, 1987
32. PSK-13/cdk4) for mammalian D type G1 cyclins. Cell 71:323-334, 1991
33. Mosmann T: Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63, 1983
34. Murate T, Kaneda T, Rifkind RA, et al: Inducer-mediated commitment of murine erythroleukemia cells to terminal division: the expression of commitment. Proc Natl Acad Sci USA 81: 3394-3398, 1984
35. Olsson L, Behnke O, Sorensen HR: Modulatory effects of 5-azacytidine, phorbol ester, and retinoic acid on the malignant phenotype of human lung cancer cells. Int J Cancer 35: 189-198, 1985
36. Pierce GB, Speers WC: Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation. Cancer Res 48:1996-2004, 1988
37. Rabson AS, Stern R. Tralka TS, et al: Hexamethylene bisacetamide induces morphologic changes and increased synthesis of procollagen in cell line from glioblastoma multiforme. Proc Natl Acad Sci USA 74:5060-5064, 1977
38. Reiss M. Gamba-Vitalo C. Sartorelli AC: Induction of tumor cell differentiation as a therapeutic approach: preclinical models for hematopoietic and solid neoplasms. Cancer Treat Rep 70:201-218, 1986
39. Reynolds T: Differentiation therapy forces cancer cells to mature. J Natl Cancer Inst 83:1209-1211, 1991
40. Richon VM, Rifkind RA, Marks PA: Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth Differ 3:413-420, 1992
41. Rutka JT, DeArmond SJ, Giblin JR, et al: Effect of retinoids on the proliferation, morphology and expression of glial fibrillary acidic protein of an anaplastic astrocytoma cell line. Int J Cancer 42:419-427, 1988
42. Rutka JT, Hubbard SL, Fukuyama K. et al: Effects of antisense glial fibrillary acidic protein complementary DNA on the growth, invasion, and adhesion of human astrocytoma cells. Cancer Res 54:3267-3272, 1994
43. Rutka JT, Smith SL: Transfection of human astrocytoma cells with glial fibrillary acidic protein complementary DNA: analysis of expression, proliferation, and tumorigenicity. Cancer Res 53:3624-3631, 1993
44. Sachs L: Growth, differentiation and reversal of malignance. Sci Am 254(1):40-47, 1986
45. Saito H, Morizane T, Watanabe T, et al: Differentiating effect of sodium butyrate on human hepatoma cell lines PLC/PRF/5. HCC-M and HCC-T. Int J Cancer 48:291-296, 1991
46. 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide. Cancer Res 50:261-265, 1990
47. Schroy P, Winawer S, Friedman E: Effect on in vivo tumorigenicity of lengthy exposure of human colon cancer cells to the differentiation agent hexamethylene bisacetamide. Cancer Lett 48:48-53, 1989
48. Schroy PC III, Carnright K, Winawer SJ, et al: Heterogeneous responses of human colon carcinomas to hexamethylene bisacetamide. Cancer Res 48:5487-5494, 1988
49. Van Dongen GAMS, Braakhuis BJM, Leyna A, et al: Antitumor and differentiation-inducing activity of N,N-dimethyl-formamide (DMP) in head and neck cancer xenografts. Int J Cancer 43:285-292, 1989
50. Walker MD, Green SB, Byar DP, et al: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303:1323-1329, 1980
51. Xiong Y, Zhang H, Beach D: D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 71:505-514, 1992
52. 131I-labelled antiglioma monoclonal antibody SZ-39 in nude mice bearing human brain tumors, in Wu BQ, Zheng J (eds): Immune-Deficient Animals in Experimental Medicine. 6th International Workshop on Immune-Deficient Animals, Beijing, 1988. Basel: Karger, 1989, pp 227-230
53. Yang WL, Du ZW, Li PX, et al: [Establishment and characteristics of monoclonal antibodies against human brain glioma.] Chinese J Cancer 7:454-457, 1988 (Chi)
54. Young CW, Fanucchi MP, Walsh TD, et al: Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight day intervals. Cancer Res 48: 7304-7309, 1988
55. Zhu JH, Du ZW, Huang Q, et al: Preclinical trials with monoclonal antibody-adriamycin immunoconjugate for the targeting chemotherapy of human brain glioma. Modern Neurosurg 2:521-532, 1991